文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

阿那白滞素在连续性肾脏替代治疗中的清除:一项体外分析

Anakinra Removal by Continuous Renal Replacement Therapy: An Ex Vivo Analysis.
PubMed 文献 · Crit Care Explor · 2023-12-14
一句话结论体外CRRT回路可在数分钟内清除阿那白滞素,血液透析模式跨膜清除率最高(5.53 mL/min),现有严重肾损害剂量可能导致CRRT患者亚治疗浓度。

该研究在闭环体外CRRT回路中评估阿那白滞素与回路的相互作用及血浆清除率,按溶质清除方式分血液滤过、血液透析和血液透析滤过三个相位,每个回路运行三次。结果显示各CRRT模式下阿那白滞素均在数分钟内从血浆中被清除,血液透析滤过时血浆平均剩余药物百分比最低(34.9%);筛过系数在血液透析滤过、血液滤过、血液透析分别为0.34、0.37、0.41,跨膜清除率在血液透析最高(5.53 mL/min),其次为血液透析滤过(4.99 mL/min)和血液滤过(3.94 mL/min)。作者认为,现有针对严重肾损害患者的剂量推荐可能使接受CRRT的患者阿那白滞素浓度低于治疗水平。

要点

  • 体外CRRT回路中,阿那白滞素在血液滤过、血液透析和血液透析滤过三种模式下均于数分钟内从血浆中被清除。
  • 血液透析滤过时血浆平均剩余药物百分比最低(34.9%);跨膜清除率血液透析最高(5.53 mL/min),血液透析滤过4.99 mL/min,血液滤过3.94 mL/min。
  • 筛过系数在血液透析滤过、血液滤过、血液透析分别为0.34、0.37、0.41。
  • 对照样本中药物剩余百分比为93.1%,各实验间保持一致,提示血中降解可忽略。
  • 作者认为,现有严重肾损害患者的剂量推荐可能使接受CRRT者阿那白滞素浓度低于治疗水平。

适用人群与场景

  • 接受连续性肾脏替代治疗(CRRT)的患者;本研究为体外回路实验,未纳入患者。

处置流程与药物剂量

  • CRRT按溶质清除方式分为三个相位:血液滤过、血液透析和血液透析滤过。
  • 阿那白滞素给予CRRT回路,采集系列滤器前血样及时间匹配的对照和血滤液样本,每个回路运行三次以评估批间变异。
  • 采用酶联免疫吸附试验测定各参考液中阿那白滞素浓度。
  • 跨膜滤器清除率通过筛过系数/透析液饱和常数与回路流率的乘积估算。

研究设计与关键结果

  • 研究类型:体外闭环CRRT回路分析;地点:大学研究实验室;无患者纳入。
  • 各CRRT模式下阿那白滞素均在数分钟内从血浆中被清除。
  • 阿那白滞素给药后血浆平均剩余药物百分比在血液透析滤过时最低(34.9%)。
  • 平均筛过系数:血液透析滤过0.34、血液滤过0.37、血液透析0.41。
  • 跨膜清除率:血液透析5.53 mL/min、血液透析滤过4.99 mL/min、血液滤过3.94 mL/min。
  • 对照样本中药物剩余百分比为93.1%,各实验间保持一致,提示血中降解可忽略。

证据类型、等级与局限

  • 证据类型:体外分析;局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,该分析首次证明阿那白滞素等大分子治疗性蛋白可被现代CRRT技术从血浆中清除。
  • 作者认为,现有严重肾损害患者的剂量推荐可能使接受CRRT者阿那白滞素浓度低于治疗水平。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Patients with sepsis are at significant risk for multiple organ dysfunction, including the lungs and kidneys. To manage the morbidity associated with kidney impairment, continuous renal replacement therapy (CRRT) may be required. The extent of anakinra pharmacokinetics in CRRT remains unknown. The objectives of this study were to investigate the anakinra-circuit interaction and quantify the rate of removal from plasma.

DESIGN: The anakinra-circuit interaction was evaluated using a closed-loop ex vivo CRRT circuit. CRRT was performed in three phases based on the method of solute removal: 1) hemofiltration, 2) hemodialysis, and 3) hemodiafiltration. Standard control samples of anakinra were included to assess drug degradation.

SETTING: University research laboratory.

INTERVENTIONS: Anakinra was administered to the CRRT circuit and serial prefilter blood samples were collected along with time-matched control and hemofiltrate samples. Each circuit was run in triplicate to assess inter-run variability. Concentrations of anakinra in each reference fluid were measured by enzyme-linked immunosorbent assay. Transmembrane filter clearance was estimated by the product of the sieving coefficient/dialysate saturation constant and circuit flow rates.

MEASUREMENTS AND MAIN RESULTS: Removal of anakinra from plasma occurred within minutes for each CRRT modality. Average drug remaining (%) in plasma following anakinra administration was lowest with hemodiafiltration (34.9%). The average sieving coefficient was 0.34, 0.37, and 0.41 for hemodiafiltration, hemofiltration, and hemodialysis, respectively. Transmembrane clearance was fairly consistent across each modality with the highest during hemodialysis (5.53 mL/min), followed by hemodiafiltration (4.99 mL/min), and hemofiltration (3.94 mL/min). Percent drug remaining within the control samples (93.1%) remained consistent across each experiment, indicating negligible degradation within the blood.

CONCLUSIONS: The results of this analysis are the first to demonstrate that large molecule therapeutic proteins such as anakinra, are removed from plasma with modern CRRT technology. Current dosing recommendations for patients with severe renal impairment may result in subtherapeutic anakinra concentrations in those receiving CRRT.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Dubinsky SDJ, Watt KM, Imburgia CE, et al. Anakinra Removal by Continuous Renal Replacement Therapy: An Ex Vivo Analysis. Crit Care Explor. 2023. PMID: 38107537. doi:10.1097/CCE.0000000000001010

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。